Acabrunat® Capsules contain Acalabrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain hematological malignancies. It is primarily indicated for patients with B-cell cancers by inhibiting abnormal B-cell signaling pathways involved in cancer cell growth and survival.
This targeted therapy offers effective disease control with improved selectivity compared to earlier BTK inhibitors.
💊 Uses / Indications
Mantle Cell Lymphoma (MCL)
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Other B-cell malignancies as prescribed by an oncologist
⚙️ Mechanism of Action
Acalabrutinib selectively inhibits Bruton’s tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway. This inhibition blocks malignant B-cell proliferation and survival, leading to reduced tumor growth.
🧪 Dosage & Administration
Take as directed by the oncologist
Usually administered orally twice daily
Capsule should be swallowed whole
Do not open, crush, or chew the capsule
⚠️ Possible Side Effects
Headache
Diarrhea
Fatigue
Muscle pain
Upper respiratory tract infections
Bruising or bleeding (rare)
🚫 Precautions & Warnings
Prescription-only medicine
Use with caution in patients with bleeding disorders
Regular monitoring recommended during therapy
Avoid concomitant use with strong CYP3A inhibitors unless advised
Not recommended during pregnancy or breastfeeding
❄️ Storage Instructions
Store below 25°C
Protect from light and moisture
Keep out of reach of children
Reviews
There are no reviews yet.